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Introduction: The main objective of the current post hoc analy-
sis was to compare patient-reported outcomes between crizotinib 
(N = 172) and chemotherapy subgroups (pemetrexed [N = 99] and 
docetaxel [N = 72]) in previously treated patients with advanced 
ALK-positive non–small-cell lung cancer, in PROFILE 1007 study 
(Pfizer; NCT0093283).
Methods: Patient-reported outcomes were assessed at baseline, day 1 
of each cycle, and end of treatment. General health status was measured 
using the EuroQol-5D visual analog scale and health utility index scores 
were assessed using the EuroQol-5D descriptive system. Functioning, 
lung cancer symptoms, and global quality of life (QOL) were assessed 
using European Organisation for Research and Treatment of Cancer 
QLQ-C30 and the QLQ-LC13 lung cancer module. Repeated measures 
mixed-effects analyses compared overall scores and change from base-
line scores, controlling for baseline scores.
Results: The overall mean EQ-5D health utility index scores (95% 
CI) on treatment were significantly greater (p < 0.05) for crizotinib 
(0.82 [0.79−0.85]) than for chemotherapy (0.73 [0.70−0.77]; 0.74 
[0.70−0.79] for pemetrexed and 0.66 [0.58−0.74] for docetaxel). A 
significantly greater improvement from baseline was observed with 
crizotinib versus pemetrexed and versus docetaxel treatment groups 
for general health status, physical functioning, global QOL, dyspnea, 
fatigue, and pain. Improvement rates for fatigue, cough, pain, dys-
pnea, and global QOL were significantly greater on crizotinib com-
pared with pemetrexed and docetaxel, respectively. Worsening rates 
for diarrhea and constipation were higher with crizotinib.
Conclusion: The benefits of crizotinib in improving symptoms and 
QOL are demonstrated regardless of whether the comparator is 
pemetrexed or docetaxel.
Key Words: Patient-reported outcomes, Quality of life, Crizotinib, 
Non–small-cell lung cancer.
(J Thorac Oncol. 2014;9: 1625–1633)
The majority of patients with lung cancer are symptomatic at initial diagnosis,1 most often with fatigue, dyspnea, cough, 
and pain.2 In addition to respiratory symptom clusters,3 non-
respiratory symptoms of psychological distress (worry, anxi-
ety) and general physical symptoms, such as loss of appetite, 
are frequent4 and difficult to palliate with current supportive 
treatments. While improving survival is a major goal of treat-
ment, palliative therapy to alleviate symptoms and optimize 
well-being without adding toxicity is prioritized by patients.5
Crizotinib (Pfizer, Inc., New York, NY) is an oral small-
molecule tyrosine kinase inhibitor (TKI) targeting ALK, 
MET, and ROS1 tyrosine kinases.6,7 The results of primary 
analyses from a randomized, controlled, open-label, phase 
III trial (PROFILE 1007) of crizotinib compared with che-
motherapy in patients with advanced, previously treated 
ALK-positive non–small-cell lung cancer (NSCLC), were pre-
viously reported.8 In the chemotherapy arm, patients received 
either docetaxel or pemetrexed depending on prior first-line 
treatment and/or tumor histology. These drugs have distinctly 
different side-effect profiles.9 Crizotinib was associated with 
a longer progression-free survival (PFS; 7.7 months ver-
sus 3.0 months for chemotherapy, hazard ratio [HR], 0.49, 
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95% confidence interval [CI], 0.37–0.64, p < 0.001), higher 
response rates (65% [95% CI, 58–72] versus 20% [95% CI, 
14–26] for chemotherapy; p < 0.001), and significantly greater 
improvement in patient-reported symptoms, global quality of 
life (QOL), and delayed time to deterioration (TTD) of pre-
specified lung cancer symptoms compared with chemother-
apy.8 The original publication did not include the results for 
patient-reported general (disease nonspecific) health status 
and health utility index for crizotinib compared with the che-
motherapy arm. Nor were results for patient-reported general 
health status, health utility scores, patient-reported symptoms, 
functioning, and QOL for crizotinib compared with the spe-
cific chemotherapy drug in the comparator arm, i.e., crizotinib 
versus pemetrexed and crizotinib versus docetaxel presented. 
Here, we present these results.
PATIENTS AND METHODS
Patient Population, Study 
Design, and Treatment
In brief, all patients had locally advanced or metastatic 
NSCLC positive for ALK rearrangement. Key eligibility crite-
ria were progressive disease after one platinum-based chemo-
therapy regimen and an Eastern Cooperative Oncology Group 
(ECOG) performance status of 0 to 2. Patients were randomly 
assigned in a 1:1 ratio to receive oral crizotinib (250 mg twice 
daily) in a 3-week cycle or intravenous chemotherapy compris-
ing either pemetrexed (500 mg/m2) or docetaxel (75 mg/m2) every 
3 weeks. The primary end point was PFS and secondary end 
points included patient-reported outcomes (PROs). This study 
was conducted in accordance with the Declaration of Helsinki, 
the International Conference on Harmonization Guidelines on 
Good Clinical Practice, and applicable local regulatory require-
ments and laws. All participants provided informed consent. 
The protocol, amendments, and informed consent forms were 
approved by an institutional review board or independent site-
specific ethics committee (see Shaw et al.8 for full details).
Questionnaires to measure PROs were self-administered 
at baseline (day 1 cycle 1) and on day 1 of every subsequent 
cycle until end of treatment prior to any testing, treatment, or 
discussion with the physician or clinic personnel. The European 
Organisation for Research and Treatment of Cancer Quality of 
Life Questionnaire core module (EORTC QLQ-C30)10 com-
prises 30 questions assessing global QOL, functioning, and 
symptoms of both multi-item and single-item measures. The 
EORTC QLQ 13-item lung cancer module (LC-13) module 
comprises 13 questions assessing lung cancer-specific symp-
toms.11 For each domain and item, a linear transformation was 
applied to standardize the raw score to a range from 0 to 100, 
with 100 representing best possible function/QOL, and high-
est symptom severity. A 10-point change from baseline in an 
item or domain is established to be clinically meaningful.12 
The EQ-5D questionnaire is a generic, non-cancer-specific 
tool that consists of the EQ-5D descriptive system that can 
be used to calculate a health utility index score and a visual 
analog scale (EQ-5D VAS) in which patients rate their current 
general health status on a scale ranging from 0 (worst imagin-
able health state) to 100 (best imaginable health state).13
Analyses
The number and percentage of patients of the total 
number eligible at each cycle who completed the QLQ-C30, 
QLQ-LC13, and EQ-5D were summarized for crizotinib, 
pemetrexed, and docetaxel at each time point. The ques-
tionnaire domains and items were scored according to the 
respective scoring algorithm.14 Comparison of the EORTC 
QLQ-C30 and LC-13 scores between crizotinib and each of 
the chemotherapy subgroups was performed as follows: (1) 
mean change from baseline scores across cycles; (2) propor-
tion of patients with improved, stable, or worsened outcomes; 
and (3) median TTD in symptoms of cough, dyspnea, and 
pain. Comparisons were performed between crizotinib and the 
pemetrexed and docetaxel subgroups. No comparisons were 
performed between the pemetrexed and docetaxel subgroups. 
Patients who had completed at least one question at baseline 
and at least at one time point on treatment (referred to as the 
PRO-evaluable population) were included in these analyses.
Mean Overall On-Treatment and 
Change from Baseline Scores
Repeated measures mixed-effects analyses15 were 
performed to compare between-treatment EQ-5D index on-
treatment scores, the EORTC QLQ C-30 and LC-13 item and 
domain scores, and EQ-5D VAS change from baseline scores 
so as to adjust for correlation between data collected across 
multiple data points for an individual. Baseline scores were 
included as control variables within the regression model. No 
adjustments were made for multiplicity of testing.
Proportion of Patients with 
Improved or Worse Outcome
Patients were classified as improved or worse for all symp-
tom and function domains, global QOL, and single items based 
on a longitudinal analysis across all time points for an individual 
patient, and using a 10-point or greater change, previously vali-
dated to be clinically meaningful.12 For analysis of functioning 
domains and global QOL, a patient was classified as improved if 
a 10-point or greater increase was observed in the average change 
from baseline scores across all available time points on treat-
ment for that patient. Similarly, a patient was classified as worse 
if a decrement of 10 points or worse was observed in the aver-
age change from baseline scores across all available time points 
for an individual patient. For analysis of symptom domains and 
single items, the classification into improved/worse categories 
was the reverse, such that a positive change indicates worsen-
ing (i.e., greater symptom severity) and a negative change indi-
cates symptom improvement. Improvement and worsening rates 
between treatments were compared using the χ2 test.
Time to Deterioration in Pain in 
Chest, Dyspnea, or Cough
TTD was calculated as the time from randomization 
to the first 10-point or greater worsening from baseline in 
chest pain, dyspnea, or cough symptoms and was summa-
rized using the Kaplan-Meier method. Patients were cen-
sored at the last time point that they completed the pain 
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in chest, dyspnea, and cough items, only if the symptoms 
had not “deteriorated” prior to this time point. The esti-
mated Kaplan-Meier plots were provided for each symp-
tom and the unstratified log-rank test used to compare the 
time to first deterioration between crizotinib and the sub-
groups of patients treated with pemetrexed or docetaxel. 
The Brookmeyer-Crowley method16 was used to derive the 
median time. The Hochberg procedure was used to adjust 
for multiple comparisons.17 A p value less than 0.05 was 
considered statistically significant.
Role of the Funding Source
The study sponsor, together with members of the 
PROFILE 1007 steering committee, was responsible for the 
study design. The sponsor collected the data and analyzed 
them in conjunction with the authors. All authors approved 
the final content of this report.
RESULTS
Patient Characteristics
The intent-to-treat population comprises 347 patients 
of whom 173 were randomized to crizotinib and 174 to che-
motherapy. A total of 99 patients (57%) received pemetrexed 
and 72 patients (41%) received docetaxel. The PRO-evaluable 
population included 162 patients in the crizotinib arm and 
151 patients in the chemotherapy arm (89 on pemetrexed and 
62 on docetaxel). Patient baseline characteristics were gen-
erally comparable among the groups (Supplementary Table 
1, Supplemental Digital Content, http://links.lww.com/JTO/
A682). A numerically higher proportion of patients who 
received pemetrexed were older than 65 years and were Asian. 
The median duration of study treatment was longer in the 
crizotinib arm (31 weeks) compared with the chemotherapy 
arm (12 weeks; 18 and 9 weeks for pemetrexed and docetaxel, 
respectively).
Compliance
At baseline, 165 of 173 patients (97%) on crizotinib 
and 162 of 171 patients (95%) on chemotherapy (97% in the 
pemetrexed and 92% in the docetaxel subgroups, respec-
tively) completed questionnaires. Compliance rate was 
defined for subsequent time points, as the percentage of 
eligible patients expected to complete QOL questionnaires 
at a time point (i.e., they had neither died nor discontin-
ued study assigned treatment). The compliance rate ranged 
after baseline over the first 10 cycles from 96% to 100% for 
crizotinib, from 93% to 97% for pemetrexed, and from 83% 
to 85% for docetaxel.
Baseline Scores
Baseline scores were comparable among the groups for 
all domains and items of the EORTC-QLQ-C30 and LC-13 
tools (Table 1). The mean (standard deviation; SD) scores at 
baseline were comparable between-treatment groups for the 
EQ-5D general health status and the EQ-5D utility index 
(Table 2). The proportion of patients reporting the presence 
of a problem at baseline for crizotinib and chemotherapy 
(pemetrexed and docetaxel), respectively, were mobility (31% 
and 32%), self-care (9% and 14%), usual activities (51% and 
52%), pain (62% and 67%), and anxiety/depression (49% and 
57%). Symptoms with the highest mean baseline scores were 
fatigue, cough, dyspnea, and pain. Compared with normative 
reference values for advanced lung cancer,14 the mean scores 
at baseline were numerically higher for physical and role func-
tioning (Table 1).
Impact on EQ-5D Health Utility Index 
and General Health Status Scores
The overall mean EQ-5D health utility index scores 
(95% CI) on treatment were significantly greater (p < 0.05) 
for crizotinib (0.82 [0.79−0.85]) than for chemotherapy 
(0.73 [0.70−0.77]; 0.74 [0.70−0.79] for pemetrexed and 0.66 
[0.58−0.74] for docetaxel). Within groups, a significant overall 
improvement from baseline in general health status (EQ-5D 
VAS) was observed for crizotinib compared with a significant 
overall deterioration for chemotherapy. Significant overall 
deterioration from baseline was also observed for the peme-
trexed and docetaxel subgroups. A greater overall improve-
ment in general health status from baseline was observed in 
the crizotinib arm compared with either pemetrexed (esti-
mated difference [95% CI]: 8.74 [4.47, 13]; p < 0.001) or 
docetaxel (estimated difference [95% CI]: 14.50 [7.82, 21.17]; 
p < 0.001) (Table 2).
Change from Baseline in Global QOL,  
Functioning, and Symptoms:  
Between-Treatment Comparison
Global QOL data demonstrated a greater improvement 
from baseline for crizotinib than for pemetrexed (p < 0.05) 
(Figure 1A) or docetaxel (p < 0.001) (Figure 1B). Compared 
with crizotinib, docetaxel was associated with worsening 
in all functional domains (physical, social, role, emotional, 
and cognitive). Although the same degree of deterioration in 
functioning was not demonstrated with pemetrexed, physical 
functioning was significantly improved on crizotinib when 
compared with pemetrexed (p < 0.05) (Figure 1A). Docetaxel 
was also associated with significantly greater worsening of 
alopecia, cough, dyspnea (QLQ C-30 and LC-13 domains), 
pain (all pain items), appetite loss, fatigue, insomnia, hemop-
tysis, peripheral neuropathy, dysphagia, and sore mouth com-
pared with crizotinib (Figure 2B, D). Similarly, pemetrexed 
was associated with a significantly (p < 0.05) greater wors-
ening of these symptoms compared with crizotinib, with the 
exception of alopecia, peripheral neuropathy, and dysphagia 
(Figure 2A, C). Concomitant use of analgesics was similar 
between the treatment arms (59.9% for crizotinib and 63.2% 
for chemotherapy). Higher antiemetic use was observed in 
the chemotherapy arm (67.3%) compared with crizotinib 
(20.3%). The only symptoms that deteriorated significantly 
(p < 0.05) from baseline on crizotinib were constipation 
(compared with pemetrexed) and diarrhea (compared with 
pemetrexed and docetaxel). No significant differences were 
observed between crizotinib and pemetrexed or docetaxel in 
overall change from baseline scores for nausea and vomiting.
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TABLE 2.  Overall EQ-5D General Health Status and Utility Index Scores on Treatment and Overall Change from Baseline by 
Treatment Subgroup (PRO-Evaluable Population)
Crizotinib  
(N = 160)
Chemotherapy  
(N = 150)
Pemetrexed  
(N = 88)
Docetaxel  
(N = 62)
EQ-5D General Health Status score at baseline, mean (SD) 64.49 (20.88) 67.49 (20.71) 68.45 (19.88) 66.15 (21.90)
EQ-5D Utility Index score at baseline, mean (SD) 0.73 (0.24) 0.70 (0.26) 0.73 (0.24) 0.67 (0.29)
Overall EQ-5D Utility Index score on treatment, mean (SE) 0.82 (0.01) 0.73 (0.02) 0.74 (0.02) 0.66 (0.04)
95% CI 0.79, 0.85 0.70, 0.77 0.70, 0.79 0.58, 0.74
p Value NA <0.001a <0.05a <0.001a
Overall EQ-5D General Health Status score on treatment, mean 73.75 63.01 65.17 58.51
95% CI (71.3, 76.2) (59.99, 66.05) (61.61, 68.72) (52.27, 64.74)
p Value <0.001a <0.001a <0.001a
Overall EQ-5D General Health Status change from baseline, mean 4.68** –6.06** –4.09* –9.46*
95% CI (2.23, 7.12) (–9.09, –3.03) (–7.65, –0.54) (–15.7, –3.23)
Difference between treatments (95% CI) 10.73 (6.85, 14.62) 8.74 (4.47, 13) 14.50 (7.82, 21.17)
p Value <0.001a <0.001a <0.001a
ap Values are for between-treatment comparisons with crizotinib.
Within treatment change from baseline *p < 0.05, **p < 0.001.
TABLE 1.  Baseline Scores: EORTC QLQ-C30 and LC-13 (PRO-Evaluable Population)
Domain
Crizotinib Chemotherapy
Chemotherapy 
(Pemetrexed Subgroup)
Chemotherapy 
(Docetaxel Subgroup)
Normative Reference 
ValuesaMean ± SD Mean ± SD Mean ± SD Mean ± SD
Global QOL (QLQ-C30) 57.6 ± 21.4 59.2 ± 22.4 59.5 ± 22.6 58.9 ± 22.2 54.7 ± 23.8
Functioning (QLQ-C30)
  Physical 76.5 ± 20.6 77.1 ± 21.2 76.9 ± 19.7 77.5 ± 23.2 65.9 ± 25.6
  Social 68.5 ± 27.5 67.7 ± 29.1 67.8 ± 29.0 67.5 ± 29.5 69.8 ± 30.3
  Role 69.8 ± 28.7 68.2 ± 29.9 68.0 ± 29.3 68.5 ± 30.9 55.5 ± 34.5
  Cognitive 85.3 ± 18.3 84.0 ± 21.9 83.0 ± 21.0 85.5 ± 23.3 81.6 ± 22.7
  Emotional 74.8 ± 21.2 74.0 ± 20.7 75.1 ± 20.8 72.4 ± 20.7 67.3 ± 24.1
Symptoms (QLQ-C30)
  Fatigue 38.2 ± 24.5 34.6 ± 25.1 35.8 ± 25.2 32.8 ± 25.0 44.2 ± 27.5
  Nausea and vomiting 8.2 ± 14.2 11.7 ± 18.2 11.8 ± 19.8 11.6 ± 15.9 10.8 ± 19.1
  Pain 23.6 ± 24.8 27.6 ± 27.2 29.4 ± 26.7 25.0 ± 27.8 34.7 ± 32.3
  Dyspnea 31.1 ± 28.3 31.8 ± 28.1 33.0 ± 28.6 30.1 ± 27.5 40.7 ± 32.2
  Insomnia 22.4 ± 26.3 27.8 ± 27.1 30.0 ± 29.3 24.7 ± 23.3 34.8 ± 33.4
  Appetite loss 23.7 ± 28.2 22.1 ± 28.3 21.3 ± 28.1 23.1 ± 28.7 31.1 ± 34.6
  Constipation 14.7 ± 25.2 16.2 ± 24.6 18.2 ± 25.7 13.4 ± 23.0 22.2 ± 31.7
  Diarrhea 9.5 ± 18.7 7.8 ± 15.6 9.5 ± 17.5 5.4 ± 12.4 7.3 ± 18.1
Symptoms (QLQ-LC13)
  Dyspnea 27.0 ± 21.8 26.9 ± 24.1 30.0 ± 25.2 22.4 ± 21.6 31.5 ± 24.6
  Cough 37.9 ± 27.0 40.9 ± 30.9 43.8 ± 33.2 36.6 ± 27.0 38.4 ± 26.6
  Hemoptysis 2.5 ± 9.5 3.8 ± 12.5 4.1 ± 14.1 3.3 ± 10.0 7.7 ± 17
  Sore mouth 5.4 ± 15.3 5.3 ± 16.9 4.9 ± 16.3 6.0 ± 17.8 5.1 ± 14.9
  Dysphagia 6.6 ± 14.8 8.0 ± 19.9 9.4 ± 20.1 6.0 ± 19.7 6.8 ± 17.8
  Peripheral neuropathy 13.9 ± 22.2 16.4 ± 26.4 16.9 ± 27.6 15.8 ± 24.8 8.9 ± 19.8
  Alopecia 17.7 ± 30.8 17.3 ± 29.8 20.2 ± 31.6 13.1 ± 26.7 5.2 ± 19.1
  Pain in chest 19.2 ± 22.9 23.6 ± 27.8 29.1 ± 28.2 15.8 ± 25.5 20.8 ± 26.6
  Pain in arm or shoulder 16.6 ± 24.2 19.0 ± 27.7 20.6 ± 28.2 16.7 ± 27.1 22.4 ± 30.1
  Pain in other parts 22.5 ± 27.1 31.7 ± 30.8 32.2 ± 30.8 31.0 ± 31.1 23.8 ± 30.9
aNormative reference values specific for advanced-stage lung cancer (stage III–IV).14
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Proportion of Patients with Improved, 
Stable, or Worsened Outcome
Statistically significant (p < 0.05) differences were seen in 
global QOL improvement rates between crizotinib and the peme-
trexed subgroup, with 42.6% versus 25.8% of patients improv-
ing, respectively (Figure 3A). Physical functioning (Figure 3A), 
fatigue, pain, appetite loss, cough, dyspnea, and pain in arm or 
shoulder (Figure 3B, C) were also improved in more patients 
on crizotinib than on pemetrexed. For example, for fatigue, 
improvement was observed in 46.3% versus 24.7% of patients 
and worsening in 16.7% versus 36% of patients on crizotinib ver-
sus pemetrexed, respectively. Similarly, for dyspnea (QLQ-C30) 
40.7% versus 28.1% improved and 16.7% versus 30.3% wors-
ened on crizotinib versus pemetrexed. The proportion of patients 
with worsening of constipation and diarrhea was statistically sig-
nificantly lower on pemetrexed than on crizotinib (Figure 3B).
Similar results were obtained for crizotinib when com-
pared with the docetaxel subgroup: global QOL improved in 
42.6% versus 12.9% of patients and worsened in 21% ver-
sus 45% of patients, respectively. Physical, emotional, and 
social functioning also improved among more patients on 
crizotinib (Figure 3A), whereas physical, role, cognitive, and 
social functioning all worsened for significantly (p < 0.05) 
more patients on docetaxel. More patients on crizotinib than 
docetaxel experienced improvement (or less worsening) for 
fatigue, pain (all items), alopecia, insomnia, appetite loss, 
cough, dyspnea (QLQ-C30 and LC-13), peripheral neuropa-
thy, and sore mouth (Figure 3B, C). No statistically significant 
differences were observed for nausea and vomiting, hemopty-
sis or dysphagia between crizotinib and either the pemetrexed 
or docetaxel subgroups (Figure 3B, C).
Time to Deterioration in Symptoms
The TTD event rate was observed to be 56% in the 
crizotinib arm, 67% in the pemetrexed subgroup, and 82% in 
the docetaxel subgroup. The median TTD for pain in chest, 
dyspnea (QLQ-LC13), or cough as a composite end point 
was 5.6 months (95% CI, 3.4–11.0 months) for the crizotinib 
arm compared with 1.9 months (95% CI, 1.4–3.0 months) for 
the pemetrexed subgroup, and 0.9 months (95% CI, 0.9–1.4 
months) for the docetaxel subgroup. Treatment with crizo-
tinib was associated with a longer TTD in symptoms of pain 
in chest, dyspnea, or cough compared with pemetrexed (HR, 
0.664; 95% CI, 0.478–0.923; p = 0.0253) (Figure 4A) or 
with docetaxel (HR, 0.374; 95% CI, 0.262–0.536; p < 0.001) 
(Figure 4B). When each symptom was analyzed separately, 
crizotinib was associated with a greater delay in TTD for 
pain in chest (median 20.8 months; 95% CI, 18.7 months—
not reached [NR]) compared with pemetrexed (median 15.4 
months; 95% CI, 9.2 months—NR; HR, 0.468; p = 0.0055) 
and docetaxel (median 3.5 months; 95% CI, 1.5 months—
NR; HR, 0.214; p < 0.001). Similarly, for dyspnea the median 
TTD for patients on crizotinib was 13.8 months (95% CI, 6.2–
18.8 months) compared with a median of 3.0 months (95% 
CI, 1.8–5.7 months; HR, 0.613; p = 0.0228), for the peme-
trexed subgroup and 2.2 months (95% CI, 1.2–4.2 months; 
HR, 0.455; p < 0.001) for the docetaxel subgroup. For cough, 
there was a longer TTD with crizotinib (median 18.8 months; 
95% CI, 12.5–22.9; p < 0.05) than with docetaxel (median 8.3 
months; 95% CI, 5.2–NR; HR, 0.528; p = 0.0138), whereas 
there was no difference for crizotinib compared with peme-
trexed (HR, 0.886; p = 0.619).The longer TTD for individual 
symptoms with crizotinib is consistent with the finding that 
FIGURE 1.  Differences between-treatment groups in overall change from baseline scores in patient-reported functioning and 
global QOL. *p < 0.05, **p < 0.001.
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there is overall improvement from baseline in these symptoms 
with crizotinib. The individual symptom median TTD is the 
time at which 50% of the patients in a treatment arm have 
reported a 10-point or greater deterioration from baseline in 
that particular symptom. A 10-point deterioration on any one 
of the symptoms included in the composite end point (deterio-
ration in one or more of cough, pain in chest, dyspnea) would 
be considered as an event for the TTD composite end point 
FIGURE 2.  Differences between-treatment groups in overall change from baseline scores in patient-reported symptoms. 
*p < 0.05, **p < 0.001.
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FIGURE 3.  Proportion of patients showing improvement and worsening in functioning, global QOL, and symptoms by 
treatment subgroup. A, Functioning domains and global QOL. B, Symptoms (EORTC QLQ C-30). C, Lung cancer symptoms 
(QLQ-LC13). *p < 0.05, **p < 0.001; NS, not significant. All p values are for comparisons versus crizotinib.
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and hence the probability of reaching the median sooner could 
increase than with each individual symptom.
DISCUSSION AND CONCLUSION
The major goals of treatment for advanced, incurable 
NSCLC are prolongation of survival, palliation of symp-
toms, and improvement in health-related QOL.18 The primary 
analysis of results for the PROFILE 1007 trial demonstrated 
significantly better objective response rate, PFS, and PROs 
for crizotinib compared with chemotherapy (pemetrexed or 
docetaxel) in patients with ALK-positive NSCLC.8 Here, 
previously unreported data are presented on general health 
status for crizotinib compared with chemotherapy, and 
post hoc subgroup analysis of PROs according to the type 
of chemotherapy received. The findings emphasize that the 
superiority of crizotinib for symptom control and QOL in 
the second-line treatment for ALK-positive NSCLC is main-
tained regardless of whether the chemotherapy comparator is 
pemetrexed or docetaxel.
The EQ-5D general health status is not specific for lung 
cancer and so gauges the generic benefit of an intervention. In 
this analysis, the baseline scores were higher (reflecting bet-
ter status), consistent with trial eligibility, than those obtained 
for an observational study of over 1000 unselected advanced-
stage NSCLC patients.2 Nevertheless, crizotinib was associ-
ated with improvement in general health status in this study 
population. In subgroup analyses, overall general health status 
worsened on docetaxel on pemetrexed. These results provide 
striking confirmation of potential for a concurrent improve-
ment in general health status alongside PFS on crizotinib, 
whereas the same is not demonstrable for either pemetrexed 
or docetaxel.
Within the chemotherapy comparator arm there was no 
randomization, and so this analysis was not designed to com-
pare docetaxel to pemetrexed. The purpose was to assess a 
differential effect of crizotinib compared with either chemo-
therapy subgroup. In a randomized comparison, docetaxel and 
pemetrexed demonstrated similar response rates and survival, 
with no differences in symptom index scores, but differed 
with respect to toxicity.9 Here, expected differences in alo-
pecia and neuropathy were observed; in addition, the degree 
of difference demonstrated by the point estimates and CIs for 
change in baseline scores (shown in Figures 1 and 2C, D) sug-
gest a greater difference for docetaxel versus crizotinib than 
for pemetrexed versus crizotinib. However, there is no symp-
tom or functional domain where the direction of benefit differs 
according to chemotherapy subgroup. Among the physician-
reported adverse events in the primary analysis,8 there was 
more nausea on crizotinib compared with chemotherapy (55% 
versus 37%). Here, patient-reported nausea did not differ sig-
nificantly for either crizotinib versus docetaxel or pemetrexed. 
This finding reinforces the value of patient-reported data for 
assessment of the impact of treatment side effects.
This is the first study to demonstrate improvement in 
lung cancer symptoms, QOL, and general health status of 
a targeted agent compared with second-line chemother-
apy. Common symptoms of cough, dyspnea, and pain were 
improved by crizotinib more than by chemotherapy, consistent 
with the results of studies comparing epidermal growth factor 
receptor TKIs (EGFR-TKIs) with first-line chemotherapy19–21 
and EGFR-TKIs compared with best supportive care in the 
second or third line.22,23 In contrast to studies of EGFR-TKIs, 
crizotinib also improved constitutional, nonrespiratory symp-
toms of fatigue (46%) and loss of appetite (33%). Effective 
FIGURE 4.  Time to deterioration in pain in chest, cough, or dyspnea.
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palliative treatments for fatigue are lacking despite this being 
as prevalent24 and distressing a symptom as dyspnea and pain 
in patients with lung cancer.2,25
The symptom and QOL improvements reported here 
are highly clinically relevant. Although statistical significance 
does not automatically imply clinical significance, the EORTC 
tools used in this trial were previously validated to be clinically 
significant at a 10-point or greater change. The EQ-5D general 
health status is not oncology specific and is a relatively ‘crude’ 
measure which could be expected to lack sensitivity to detect 
a change in our population if the differential treatment effect 
is small. This reinforces the clinical relevance of the statisti-
cally significant improvement in general health status observed 
with this tool for crizotinib but not for either type of chemo-
therapy. PROs are arguably more representative of the patient 
perspective than physician-reported outcomes. In addition, 
adaptation to symptoms by patients can occur such that they 
are “downplayed.”26 The open-label trial design could be con-
sidered as a potential limitation of this study because patients 
could be biased in their self-reported assessments based on 
treatment expectations. Although open-label, the study had an 
active comparator; therefore, the potential for bias is relatively 
reduced compared with a placebo-controlled study. Different 
rates of attrition between-treatment groups, which is very com-
mon in oncology studies like the current one, could be consid-
ered another limitation as it influences the number of patients 
eligible to complete a questionnaire at the various time points.
PROs are required by physicians, payers, regulators, and 
patients for full assessment of the benefit-risk profile, particu-
larly in the context of PFS.27 In conclusion, using generic and 
oncology-specific measures, crizotinib demonstrates consis-
tent improvement, compared with single-agent chemotherapy 
(docetaxel or pemetrexed), in key respiratory symptoms of 
cough, dyspnea, and pain; constitutional symptoms of fatigue 
and loss of appetite; and a positive impact on global QOL, 
functional domains, and general health status. Physician-
reported adverse events such as nausea and patient-reported 
gastrointestinal symptoms that were worse on crizotinib than 
chemotherapy did not impact negatively on global QOL. 
Improvement in general health status was observed on crizo-
tinib but not on either chemotherapy. These results reinforce 
the positive benefit-risk profile of crizotinib in previously 
treated patients with ALK-positive advanced NSCLC.
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